Linkov Igor, Satterstrom F Kyle, Corey Lisa M
US Army Engineer Research and Development Center, Brookline, Massachusetts 02446, USA.
Nanomedicine. 2008 Jun;4(2):167-71. doi: 10.1016/j.nano.2008.01.001. Epub 2008 Mar 10.
Current nanomaterial research is focused on the medical applications of nanotechnology, whereas side effects associated with nanotechnology use, especially the environmental impacts, are not taken into consideration during the engineering process. Nanomedical users and developers are faced with the challenge of balancing the medical and societal benefits and risks associated with nanotechnology. The adequacy of available tools, such as physiologically-based pharmacokinetic modeling or predictive structure-activity relationships, in assessing the toxicity and risk associated with specific nanomaterials is unknown. Successful development of future nanomedical devices and pharmaceuticals thus requires a consolidated information base to select the optimal nanomaterial in a given situation--understanding the toxicology and potential side effects associated with candidate materials for medical applications, understanding product life cycle, and communicating effectively with personnel, stakeholders, and regulators. This can be achieved through an innovative combination of toxicology, risk assessment modeling, and tools developed in the field of multicriteria decision analysis (MCDA).
当前的纳米材料研究主要集中在纳米技术的医学应用上，而在工程过程中并未考虑与纳米技术使用相关的副作用，尤其是对环境的影响。纳米医学的使用者和开发者面临着平衡纳米技术带来的医学和社会效益与风险的挑战。诸如基于生理的药代动力学建模或预测性构效关系等现有工具在评估特定纳米材料的毒性和风险方面是否充分尚不清楚。因此，未来纳米医疗设备和药物的成功开发需要一个综合的信息库，以便在特定情况下选择最佳的纳米材料——了解与医疗应用候选材料相关的毒理学和潜在副作用，了解产品生命周期，并与人员、利益相关者和监管机构进行有效沟通。这可以通过毒理学、风险评估建模以及多准则决策分析（MCDA）领域开发的工具的创新组合来实现。
